Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 621 to 630 of 2208 total matches.

Rifaximin (Xifaxan) for Irritable Bowel Syndrome with Diarrhea

   
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015  (Issue 1474)
to treat IBS-C that has not responded to fiber and laxatives.1,2 MECHANISM OF ACTION — Rifaximin ...
Rifaximin (Xifaxan – Salix), a minimally absorbed oral antibiotic approved previously to treat travelers' diarrhea and to reduce the risk of recurrent hepatic encephalopathy, has now been approved by the FDA for treatment of irritable bowel syndrome with diarrhea (IBS-D). Eluxadoline (Viberzi – Actavis), a mu-opioid receptor agonist, was also recently approved for IBS-D and will be reviewed in a future issue.
Med Lett Drugs Ther. 2015 Aug 3;57(1474):109-11 | Show Introduction Hide Introduction

Polidocanol (Varithena) for Varicose Veins

   
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015  (Issue 1474)
and stripping.1 A meta-analysis of 13 randomized controlled trials in ˃3000 patients with great saphenous ...
An injectable foam formulation of the sclerosing agent polidocanol (Varithena – Provensis/BTG) has been approved by the FDA for treatment of incompetent veins and visible varicosities of the great saphenous vein system. It is the first foam therapy to be approved for this indication, but polidocanol and other sclerosants have been used for years as foam formulations compounded by physicians. Polidocanol is also available in a liquid formulation (Asclera) to treat smaller veins. Sodium tetradecyl sulfate (Sotradecol) is FDA-approved in a liquid formulation for use in...
Med Lett Drugs Ther. 2015 Aug 3;57(1474):111-2 | Show Introduction Hide Introduction

In Brief: Duopa - A Carbidopa/Levodopa Enteral Suspension for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015  (Issue 1474)
.24 hours with immediaterelease tablets.1 Duopa is available in a 100-mL single-use cassette containing 4 ...
The FDA has approved Duopa (Abbvie), a carbidopa/levodopa enteral suspension, for treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). It has been available in Europe since 2001.In patients with advanced PD, emptying of the stomach may be delayed and unpredictable, which can affect the rate and amount of absorption of carbidopa/levodopa and its efficacy. To bypass the stomach, the new formulation is delivered through a nasojejunal (NJ) tube or percutaneous endoscopic gastrostomy with jejunal (PEG-J) tube.A randomized, double-blind, active-controlled, 12-week...
Med Lett Drugs Ther. 2015 Aug 3;57(1474):112 | Show Introduction Hide Introduction

Aptensio XR - Another Long-Acting Methylphenidate for ADHD

   
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015  (Issue 1473)
of Aptensio XR for 2-4 weeks, followed by crossover treatment for 1 week each with placebo and the new ...
The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain multilayer beads designed to provide both a rapid onset and a long duration of action. This formulation of methylphenidate has been available in Canada as Biphentin since 2006.
Med Lett Drugs Ther. 2015 Jul 20;57(1473):101-3 | Show Introduction Hide Introduction

Prestalia - Another Combination for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015  (Issue 1473)
, and generics).1 Two other ACE inhibitor/calcium channel blocker combinations, benazepril/amlodipine (Lotrel ...
The FDA has approved Prestalia (Symplmed), an oral fixed-dose combination of the dihydropyridine calcium channel blocker amlodipine (Norvasc, and generics) and a new salt form of the angiotensin-converting enzyme (ACE) inhibitor perindopril, for treatment of hypertension in patients not adequately controlled on monotherapy or already taking both drugs, and in those just starting therapy who are likely to need multiple drugs to control their blood pressure. The new salt form (perindopril arginine) is more stable and has a longer shelf-life than perindopril erbumine (Aceon, and generics). Two...
Med Lett Drugs Ther. 2015 Jul 20;57(1473):103-4 | Show Introduction Hide Introduction

Namzaric - A Combination of 2 Old Drugs for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015  (Issue 1473)
or reverse the underlying neurodegenerative process.1 Many patients with moderate to severe AD are treated ...
The FDA has approved Namzaric (Forest), a fixed-dose combination of extended-release (ER) memantine (Namenda XR), an NMDA-receptor antagonist, and donepezil (Aricept, and generics), an acetylcholinesterase inhibitor, for treatment of moderate to severe Alzheimer's type dementia in patients previously stabilized on both drugs. The patent for Namenda has recently expired and generic formulations of memantine 5- and 10-mg tablets have been approved.
Med Lett Drugs Ther. 2015 Jul 20;57(1473):105-6 | Show Introduction Hide Introduction

Liletta - A Third Levonorgestrel-Releasing IUD

   
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015  (Issue 1472)
IUDs (see Table 1), but the manufacturer offers programs that significantly reduce the cost ...
The FDA has approved Liletta, an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy for up to 3 years. The fourth IUD to be approved in the US, and the third that releases levonorgestrel, Liletta is comarketed by Actavis and Medicines360, a nonprofit women's health pharmaceutical company. The wholesale cost of Liletta is similar to that of other IUDs (see Table 1), but the manufacturer offers programs that significantly reduce the cost for commercially-insured patients and clinics serving low-income women.
Med Lett Drugs Ther. 2015 Jul 6;57(1472):99-100 | Show Introduction Hide Introduction

Ryanodex - A New Dantrolene Formulation for Malignant Hyperthermia

   
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015  (Issue 1472)
for treatment of malignant hyperthermia for many years.1 THE NEW FORMULATION — Ryanodex is available ...
The FDA has approved a new IV formulation of dantrolene (Ryanodex – Eagle) for prevention and treatment of malignant hyperthermia in adults and children. The new formulation requires fewer vials, less fluid volume, and less time for preparation and administration than other available IV dantrolene products (Dantrium, Revonto).
Med Lett Drugs Ther. 2015 Jul 6;57(1472):100 | Show Introduction Hide Introduction

Eliglustat (Cerdelga) - An Oral Drug for Gaucher Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015  (Issue 1472)
of adults with type 1 Gaucher disease. Eliglustat is metabolized primarily by CYP2D6. Because patients who ...
The FDA has approved eliglustat (Cerdelga – Genzyme), an oral glucosylceramide synthase inhibitor, for treatment of adults with type 1 Gaucher disease. Eliglustat is metabolized primarily by CYP2D6. Because patients who are CYP2D6 ultra-rapid metabolizers may not achieve therapeutic concentrations and a specific dosage cannot be recommended for indeterminate metabolizers, the FDA has approved the drug only for patients who are extensive, intermediate, or poor metabolizers of CYP2D6.
Med Lett Drugs Ther. 2015 Jul 6;57(1472):e100-101 | Show Introduction Hide Introduction

Liraglutide (Saxenda) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
Liraglutide (Saxenda) for Weight Loss The injectable glucagon-like peptide-1 (GLP-1) receptor agonist ...
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, previously approved by the FDA for treatment of type 2 diabetes as Victoza, has now also been approved at a higher dose as Saxenda (Novo Nordisk) for chronic weight management in adults with a BMI ≥30, or a BMI ≥27 with a weight-related comorbidity such as hypertension, dyslipidemia, or diabetes.
Med Lett Drugs Ther. 2015 Jun 22;57(1471):89-90 | Show Introduction Hide Introduction